The largest genome-wide association study (GWAS) ever performed on osteoarthritis has uncovered over 900 genetic associations.
More than 500 of these associations had never been reported before, providing fresh insights into the genetic landscape of the disease.
By integrating diverse biomedical datasets, the researchers identified 700 genes with high confidence as being involved in osteoarthritis. Notably, 10 per cent of these genes encode proteins that are already targeted by approved drugs, opening the door to drug repurposing opportunities that could accelerate treatment development.
“With ten percent of our genetic targets already linked to approved drugs, we are now one step closer to accelerating the development of effective treatments for osteoarthritis,” explains study leader Professor Eleftheria Zeggini, director of the Institute of Translational Genomics at Helmholtz Munich and Professor of Translational Genomics at the Technical University of Munich.
Beyond identifying genetic targets with therapeutic potential, the study also provides valuable insights that could help tailor treatment strategies. “Genetic variants associated with osteoarthritis risk are widespread across osteoarthritis patients,” said co-first author Dr. Konstantinos Hatzikotoulas.
“Our newly gained knowledge about them can enable improved patient selection for clinical trials and personalised medicine approaches.”
In addition to these genetic insights, the scientists identified eight key biological processes crucial to osteoarthritis development, including the circadian clock and glial cell functions.
“Our discovery suggests that targeted interventions regulating one or more of these eight processes could play another significant role in slowing or even halting disease progression,” Hatzikotoulas said.
“What we found in the largest osteoarthritis GWAS study not only advances our understanding of the disease but also lays the groundwork for developing more effective and personalised therapies that could transform osteoarthritis care,” said Eleftheria Zeggini.
